Entrada Therapeutics shares plunge after trial data misses expectations
Updated
Updated · Benzinga · May 7
Entrada Therapeutics shares plunge after trial data misses expectations
10 articles · Updated · Benzinga · May 7
The stock fell 59.48% to $7.00 after Phase 1/2 ELEVATE-44-201 data showed dystrophin rose 2.36% from a 4.00% baseline in exon 44 skipping DMD patients.
Investors had focused on roughly 10% dystrophin improvement, though the company said treated participants showed statistically significant improvement versus placebo in Time to Rise velocity.
Entrada has begun dosing Cohort 2 at 12 mg/kg and expects results by the end of 2026, as the weak efficacy readout overshadowed the functional signal.
After a 60% stock crash, can a higher dose save Entrada's DMD drug from rivals with far superior data?
As another exon-skipping drug stumbles, are gene editing and therapy now the only true hopes for Duchenne patients?